top of page



Proteomics International (PI) is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The Company specializes in the area of proteomics – the industrial-scale study of the structure and function of proteins.

Proteomics International’s aim is to use its protein expertise to develop and commercialize diagnostic tests for chronic diseases with unmet medical needs.

PI is executing a stepped rollout of its flagship diagnostic test for diabetic kidney disease. Successful commercialization of PromarkerD provides the opportunity to enjoy ongoing returns through licensing fees and royalty payments, as is the case of the strategic alliance with OMICS GLOBAL SOLUTIONS for the development and commercialization of its brand INNOVATIO-ND2 based on the PI's protected technology and algorithm.



Nextgen Proteomics

CDI, the result of intensive efforts and advances developed by the High-Throughput Biology Center at Johns Hopkins University, is a privately owned research and discovery company in the field of proteomics.

The company was created by scientists for scientists, addressing the critical needs required in order to accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health.

  • The Science, Research and Technology Trust, Facilitates and increases the ability to continually advance the economy of Puerto Rico and the welfare of its citizens through innovative companies of science and technology, as well as its industrial base.

  • OMICS has its office in Suite 206 of the PR Science and Technology Trust.



Macrotech is a major health related distributor in the Dominican Republic, with the highest standards of excellence for patients, payers and doctors.

Macrotech became the 1st Omics distributor in Latin-America.

Among the most solid companies dedicated to the health sector in the Dominican Republic, Macrotech becomes the first company to distribute INNOVATIO ND2 in a Latin American country with OMICS. Being strategic partners that share the same vision on the criticality of caring for the kidney health of the diabetic population.


Many years ago, experienced professionals from the Reference Laboratory and Medical Care Services Industry decided to combine their knowledge to offer better services to the Health Industry and the population of Puerto Rico. This industry has been more demanding in the face of new challenging costs and other factors. Immuno Reference Lab is proud to assist its service partners by offering low cost and cutting edge services, including INNOVATIO ND2™


It provides service to more than 463 clinical laboratories, 42 hospitals, 26 diagnostic and treatment centers (CDTs), 330 centers and employer groups and was the first commercial laboratory in Puerto Rico to offer informed test results to our clients through the web. customers.


One of the most prestigious renal services companies in CHILE; they position their actions with innovative thinking, changing strategy if necessary but keeping their goal of supporting CKD prevention and treatment clear and firm from different fronts.

Since 2022, representing OMICS and the introduction of INNOVATIO-ND2 to the Chilean market through a strategic alliance to develop this south american country as the pioneer bringing our solution to the millions of diabetic patients with need to know their risk of developing renal disease. 

bottom of page